Press Releases

BioMS Medical Secures Long-Term Manufacturing Agreements for Multiple Sclerosis Drug

Edmonton, Alberta, February 15, 2006 - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), announced that it has secured long-term manufacturing agreements with two global companies, UCB-Bioproducts and Hospira Worldwide Inc., for its lead MS drug MBP8298.

Under the terms of the agreements, UCB-Bioproducts will continue to manufacture the MBP8298 bulk drug and Hospira will fill and finish the drug product into vials for use in patients. These contracts contemplate these companies providing their services through the current pivotal clinical trial for MBP8298 and into commercial production.
“These agreements emphasize our commitment to bring a quality, first-in-class therapeutic to MS patients and are important to the success of the anticipated future launch of MBP8298 into the marketplace,” said Kevin Giese, President of BioMS Medical. “Both UCB and Hospira are public companies, world-leaders in quality manufacturing and recognized experts in their field of work.”

About UCB
With more than 30 years of experience dedicated to peptide API contract manufacturing, UCB-Bioproducts is the world-leader in pharmaceutical peptides and peptidomimetics’, supporting customers’ projects with services from preclinical to commercialization through clinical development. UCB-Bioproducts is a division of UCB, a global biopharmaceutical leader headquartered in Brussels, Belgium, with manufacturing facilities in Europe, US and Sales and Marketing offices in Europe, US and Japan. UCB employs over 8,500 people operating in over 40 countries worldwide. More information is available on www.ucb-bioproducts.com.

This press release may contain forward-looking statements, which reflect the Corporation’s current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Corporation’s ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that dirucotide (MBP8298) will continue to demonstrate a satisfactory safety profile in ongoing and future clinical trials; and that BioMS Medical Corp. will complete the respective clinical trials within the timelines communicated in this release. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.